3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Carcinoma, Non-Small-Cell Lung
12
Carcinoma, Medullary
9
Lung Neoplasms
8
Thyroid Neoplasms
7
Neoplasms
5
Neoplasm Metastasis
5
Squamous Cell Carcinoma of Head and Neck
3
Prostatic Neoplasms
3
Ovarian Neoplasms
3
Carcinoma, Renal Cell
3
Breast Neoplasms
3
Stomach Neoplasms
2
Pleural Effusion
2
Kidney Neoplasms
2
Gliosarcoma
2
Glioblastoma
2
Familial medullary thyroid carcinoma
2
Fallopian Tube Neoplasms
2
Urinary Bladder Neoplasms
1
Thyroid cancer, medullary
1
Thyroid Diseases
1
Thyroid Cancer, Papillary
1
Small Cell Lung Carcinoma
1
Recurrence
1
Rectal Neoplasms
1
Precancerous Conditions
1
Peritoneal Neoplasms
1
Oligodendroglioma
1
Multiple Endocrine Neoplasia Type 2b
1
Multiple Endocrine Neoplasia Type 2a
1
Interventions
Cetuximab
4
Radiosurgery
3
Nivolumab
3
Ipilimumab
3
pembrolizumab
2
Vorinostat
2
N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl-6-(5-((methylsulfonyl)ethyl)aminomethyl)-2-furyl)-4-quinazolinamine
2
Magnetic Resonance Spectroscopy
2
Lapatinib
2
Dasatinib
2
Cisplatin
2
CTLA-4 Antigen
2
Bevacizumab
2
temsirolimus
1
ispinesib
1
eribulin
1
dehydroftorafur
1
apalutamide
1
amivantamab
1
alectinib
1
Specimen Handling
1
Sorafenib
1
Sirolimus
1
Platinum
1
Pilocarpine
1
Pemetrexed
1
Oral Hygiene
1
NVP-BKM120
1
Moxibustion
1
MK 2206
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Has results
×
Salivary Gland Neoplasms
×
vandetanib
×
Clear all
No trials found.